Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski; Jerzy Samochowiec

doi:10.5114/fpn.2022.117700

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

1/2022
vol. 38

Send email

Copy url:

Review article

Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski

¹

,

Jerzy Samochowiec

¹

Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland;
Katedra i Klinika Psychiatrii, Pomorski Uniwersytet Medyczny, Szczecin, Polska

Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 35–47

DOI: https://doi.org/10.5114/fpn.2022.117700

Online publish date: 2022/08/02

Article file

- 03R_IPiN_FARM_2022-1C.pdf [0.91 MB]

Get citation

PlumX metrics:

1. Blier P, Oquendo MA, Kupfer DJ. Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology 2017; 42(10), 1927-1928; https://doi.org/10.1038/npp.2017.33.

2. Carlsson A. A Paradigm Shift in Brain Research. Science 2001; 294(5544), 1021-1024; https://doi.org/10.1126/science.1066969.

3. Gorwood P, Frangou S, Heun R. Editorial: Neuroscience-based Nomenclature (NbN) replaces the current label of psychotropic medications in European Psychiatry. European Psychiatry 2017; 40 (July 2016): 123; https://doi.org/10.1016/j.eurpsy.2016.07.009.

4. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 2000; 57(5), 503-509. https://doi.org/10.1001/archpsyc.57.5.503.

5. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Canadian Journal of Psychiatry 2016; 61(9), 540-560; https://doi.org/10.1177/0706743716659417.

6. Kickbusch I, Piselli D, Agrawal A, Balicer R, Banner O, Adelhardt M et al. The Lancet and Financial Times Commission on governing health futures 2030: growing up in a digital world. The Lancet 2021; 398(10312), 1727-1776; https://doi.org/10.1016/S0140-6736(21)01824-9.

7. Prieto E, Micó JA, Meana JJ, Majadas S. Neurobiological basis of quetiapine’s antidepressant effect in the bipolar disorder. Actas Espanolas de Psiquiatria 2010; 38(1), 22-32.

8. Rønning M, Blix HS, Harbø BT, Strøm HS. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – Are drug utilisation data comparable? European Journal of Clinical Pharmacology 2000; 56 (9-10), 723–727; https://doi.org/10.1007/s002280000200.

9. Siafis S, Davis JM, Leucht S. Antipsychotic drugs: from ‘major tranquilizers’ to Neuroscience-based-Nomenclature. Psychological Medicine 2021; 51(3), 522-524; https://doi.org/10.1017/S0033291719003957.

10. Tang SW, Tang WH, Leonard BE. Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature. World Journal of Biological Psychiatry 2019; 20(8), 586-604; https://doi.org/10.1080/15622975.2017.1346279.

11. Uchida H. Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next? Psychiatry and Clinical Neurosciences 2018; 72(2), 50-51; https://doi.org/10.1111/pcn.12615.

12. Unterecker S. Compliance and Psychoeducation. In: NeuroPsychopharmacotherapy. Springer International Publishing 2020; pp. 1-9; https://doi.org/10.1007/978-3-319-56015-1_6-1.

13. Urban S, Raś P. Treatment of anxiety disorders. Dialogues in Clinical Neuroscience 2017; 19(2), 93-107; https://doi.org/10.31887/DCNS.2017.19.2/bbandelow.

14. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC classification and DDD assignment; 2000.

15. Wilson S. Naming the drugs we use: neuroscience-based nomenclature, a helpful innovation. Therapeutic Advances in Psychopharmacology 2018; 8(6), 171-172; https://doi.org/10.1177/2045125318762065.

16. Zohar J, Kasper S. Neuroscience-based Nomenclature (NbN): A call for action. World Journal of Biological Psychiatry 2016; 17(5), 318-320; https://doi.org/10.1080/15622975.2016.1193626.

17. Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology 2015; 25(12), 2318-2325; https://doi.org/10.1016/j.euroneuro.2015.08.019.

Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski 1 , Jerzy Samochowiec 1

Piotr Podwalski

¹

,

Jerzy Samochowiec

¹